Drugs / Difinsa53
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02534129 | Aug 2015 → Mar 2016 | radiodermatitis | ProTechSure Scientific, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Difinsa53 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02534129 ↗ |
| Known as | DIFINISA53 | “The proposed study seeks to evaluate the efficacy of DIFINISA53™, a safe silibin-based skin cream, on preventing radiation dermatitis (RD) when compared to an over the counter...” NCT02534129 ↗ |
| Route | Topical | “Difinsa53 cream is applied to one half of radiation field” NCT02534129 ↗ |